Literature DB >> 3475196

Effect of prophylactic intravenous ceftriaxone in maxillofacial surgery.

P Stoll.   

Abstract

Cephalosporins are commonly used in maxillofacial surgery because they achieve high concentrations in bone. Prophylactic antibiotic therapy was given to 65 patients undergoing diverse surgical procedures. 20 patients received cefotiam in 2 doses of 2 g for 5 days; 15 patients received cefotiam in 2 doses of 2 g only perioperatively. No difference was found between these two groups with respect to prophylactic protection against infection. A further 15 patients received ceftriaxone in a single dose of 2 g preoperatively. Since we found that local infection and febrile morbidity was not significantly different even in the 'one-shot' group, we investigated the effect of 'low-dose' prophylaxis with only 1 g ceftriaxone preoperatively in another 15 patients. We found that this dose was sufficient to prevent infection in patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3475196     DOI: 10.1159/000238510

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  4 in total

1.  Summary of the scientific literature for pain and anxiety control in dentistry journal literature, January 1986-December 1987.

Authors:  L C Hassett
Journal:  Anesth Prog       Date:  1988 Nov-Dec

2.  [Perioperative antibiotic prophylaxis in maxillofacial surgery].

Authors:  H A Merten; F Halling
Journal:  Infection       Date:  1993       Impact factor: 3.553

Review 3.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

4.  A meta-analysis of randomized, controlled trials assessing the prophylactic use of ceftriaxone. A study of wound, chest, and urinary infections.

Authors:  J C Woodfield; N Beshay; A M van Rij
Journal:  World J Surg       Date:  2009-12       Impact factor: 3.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.